AKEBIA THERAPEUTICS, INC. Fair Value Adjustment of Warrants
AKEBIA THERAPEUTICS, INC. (AKBA) reported Fair Value Adjustment of Warrants of -$566.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$566.00K, a 108.11% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$456.00K.
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$2.26M, a 235.04% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$1.46M, a 271.03% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2025 was $3.10M, a 839.09% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2024 was $330.00K.
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2023 was $0.00.
- AKEBIA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2017 was $3.41M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$566.00K 10-Q · filed 2026-08-05 | -$1.02M 10-Q · filed 2026-08-05 | -$3.28M derived: sum of 3 quarters · filed 2026-08-05 | -$4.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$456.00K 10-Q · filed 2026-05-07 | -$2.72M derived: sum of 2 quarters · filed 2026-05-07 | -$4.18M derived: sum of 3 quarters · filed 2026-05-07 | $2.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.73M derived: sum of 2 quarters · filed 2026-02-26 | $3.25M derived: sum of 3 quarters · filed 2026-08-05 | $3.10M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.46M 10-Q · filed 2025-11-10 | $5.52M derived: sum of 2 quarters · filed 2026-08-05 | $5.36M 10-Q · filed 2025-11-10 | $7.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $6.98M 10-Q · filed 2026-08-05 | $6.83M 10-Q · filed 2026-08-05 | $8.50M derived: sum of 3 quarters · filed 2026-08-05 | $9.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$155.00K 10-Q · filed 2026-05-07 | $1.52M derived: sum of 2 quarters · filed 2026-05-07 | $2.38M derived: sum of 3 quarters · filed 2026-05-07 | $45.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.53M derived: sum of 2 quarters · filed 2026-02-26 | $200.00K derived: sum of 3 quarters · filed 2026-02-26 | $330.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $856.00K 10-Q · filed 2025-11-10 | -$1.48M derived: sum of 2 quarters · filed 2025-11-10 | -$1.34M 10-Q · filed 2025-11-10 | -$1.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$2.33M 10-Q · filed 2025-08-07 | -$2.20M 10-Q · filed 2025-08-07 | -$2.20M derived: sum of 3 quarters · filed 2026-02-26 | -$2.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $129.00K 10-Q · filed 2025-05-08 | $129.00K derived: sum of 2 quarters · filed 2026-02-26 | $129.00K derived: sum of 3 quarters · filed 2026-02-26 | $129.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $3.41M 10-K · filed 2020-03-12 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $3.41M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $3.41M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $3.41M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |